UBS AM’s Bioverativ Inc. Common Stock BIVV Stock Holding History

UBS AM’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-131,573	Closed	-$7.09M	–	2691
2017 Q4	$7.09M	Buy	131,573 +5,706	+5%	+$312K	0.01%	1000
2017 Q3	$7.18M	Sell	125,867 -240,407	-66%	-$14.1M	0.01%	980
2017 Q2	$22M	Sell	366,274 -530,766	-59%	-$30.2M	0.02%	712
2017 Q1	$48.9M	Buy	+897,040	New	+$44.2M	0.05%	402

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

UBS AM's BIVV Position: Q1 2018 in Review

UBS AM sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 131,573 shares — an estimated $7.09M sold.

UBS AM first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $48.9M in Q1 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

UBS AM reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
UBS AM sold 131,573 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $7.09M.
UBS AM first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
UBS AM's Bioverativ Inc. Common Stock position peaked at $48.9M in Q1 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on UBS AM's 13F filing for Q1 2018, filed 14 May 2018.